Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
2005 StandoutNobel
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function
2007 StandoutNobel
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Untangling the ErbB signalling network
2001 Standout
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
2021 StandoutNobel
Extracellular matrix binding mixed micelles for drug delivery applications
2009 StandoutNobel
Southwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth Factors
1993
The Clinical Spectrum of Lymphatic Disease
2008
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides
1999
The biology and management of non-small cell lung cancer
2018 StandoutNature
From bench to clinic with apoptosis-based therapeutic agents
2000 Nature
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594
2001
De novo protein design. I. in search of stability and specificity
1999 StandoutNobel
Promoting apoptosis as a strategy for cancer drug discovery
2005
A cytokine-mediated link between innate immunity, inflammation, and cancer
2007 Standout
Lymphangiogenesis: Molecular Mechanisms and Future Promise
2010 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Current development of mTOR inhibitors as anticancer agents
2006
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
In vitro selection of DNA aptamer against abrin toxin and aptamer-based abrin direct detection
2006
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
The Bcl2 family: regulators of the cellular life-or-death switch
2002 Standout
The development of androgen-independent prostate cancer
2001 Standout
Upregulation of bcl‐2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines
2001
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma
2000
Drug targeting
2000 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Targeting cancer with small molecule kinase inhibitors
2008 Standout
New Approaches and Therapeutics Targeting Apoptosis in Disease
2005
Antisense therapy for cancer
2005
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
Cisplatin resistance and oncogenes - a review
2000
Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells
2004
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine
2001
Oncomirs — microRNAs with a role in cancer
2006 Standout
The health-related quality of life and survival of small-cell lung cancer patients: Results of a companion study to CALGB 9033
2002
Treatment of Cutaneous T Cell Lymphoma
2002
Adhesion receptors of the immune system
1990 StandoutNature
The Benefits of Frequent Positive Affect: Does Happiness Lead to Success?
2005 Standout
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl‐2 and Bcl‐xL antisense treatment
2003
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas
2003
Chemistry in living systems
2005 StandoutNobel
Role of gemcitabine in cancer therapy
2005
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
2000
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
2008 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Nanoparticles, Proteins, and Nucleic Acids: Biotechnology Meets Materials Science
2001 Standout
The BCL-2 protein family: opposing activities that mediate cell death
2007 Standout
Gefitinib (ZD1839, Iressa®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspective
2005
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
2001
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
2009 StandoutNature
Peripheral T- cell lymphomas: diagnosis and management
2003
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Functional Nucleic Acid Sensors
2009 Standout
A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.
2000
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's Lymphoma
1999
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Apoptosis: A Review of Programmed Cell Death
2007 Standout
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Cell Surface Antigen and Molecular Targeting in the Treatment of Hematologic Malignancies
2002
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
New Strategies for Fluorescent Probe Design in Medical Diagnostic Imaging
2009 Standout
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
2003
Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.
2011
Association of the VLA a Subunit with a Novel Protein
1989
Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy.
1992
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Monoclonal Antibody Therapy for Cancer
2003
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer
1999
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
2011
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Immunotoxins for targeted cancer therapy
1998
mTOR: a pharmacologic target for autophagy regulation
2015 Standout
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
1999 Standout
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
1999
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors
2000
Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
2001
Works of R. Stahel being referenced
Adenocarcinoma, a molecular perspective
2007
Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
2003
Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer
1994
Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer
1992
Weekly carboplatin and VM-26 for elderly patients with small-cell lung cancer
1994
Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen
1990
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
1998
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of Hodgkin's disease
2005
Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine
1995
Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines
1998
Original article: Placebo controlled phase I/II study of subcutaneous GM-CSF in patients with germ cell tumors undergoing chemotherapy
1990
Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer
1997
Maffucci’s Syndrome
2001
Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project
2012
A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
2000
Imaging and therapy of small cell carcinoma xenografts using 131I-labeled monoclonal antibody SWA11
1990
3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
2015
Cytotoxic murine monoclonal antibody LAM8 with specificity for human small cell carcinoma of the lung
1987
Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer
1991